SYNAGEVA BIOPHARMA ANNOUNCES CLOSING OF PUBLIC OFFERING AND EXERCISE OF OVER-ALLOTMENT OPTION
SYNAGEVA BIOPHARMA ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK
Sandford D. Smith Joins Tullis Health Investors As Managing Director
`